FDA OKs Pfizer’s HYMPAVZI™ (marstacimab-hncq) for Hemophilia A or B Without Inhibitors
- HYMPAVZI’s approval is based on Phase 3 study results demonstrating substantial bleed reduction compared to routine prophylaxis and on-demand treatment in eligible patients with hemophilia A or B without inhibitors
- In the U.S., HYMPAVZI is the first once-weekly subcutaneous prophylactic treatment for eligible people living with hemophilia B, and the first to be administered via a pre-filled pen or syringe for eligible people living with hemophilia A or B
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.